0

Cinepazide Maleate Improves Cognitive Function and Protects Hippocampal Neurons in Diabetic Rats With Chronic Cerebral Hypoperfusion

Yumei Li, Ting Zhang, Xiaojie Zhang, Wenying Zou, Xian Gong, Jianliang Fu

Biol Pharm Bull. 2017 Mar 1;40(3):249-255.

PMID: 27990002

Abstract:

To determine the combined effect of type 2 diabetes (T2D) and chronic cerebral hypoperfusion (CCH) on learning and spatial memory, we developed a rat model of CCH by permanent occlusion of bilateral common carotid arteries (2-vessel occlusion (2VO)) in high-fat diet (HFD)-fed rats injected with low-dose streptozotocin (STZ). Furthermore, we examined the effect of cinepazide maleate (CM) on cognitive deficits and brain damage in this rat model. Rats were maintained on HFD for 6 weeks and then injected with 35 mg/kg STZ to induce T2D. Sham or 2VO surgery was performed in non-diabetic or diabetic (DM) rats to obtain four groups: blank, DM, CCH, and DM-CCH groups. Cognitive function was tested by the Morris water maze (MWM) test. To determine the effects of the vasodilator cinepazide maleate (CM) on cognitive deficits and brain damage, DM-CCH rats were administered with 10 mg/kg CM or saline daily for 14 d. Neuronal damage in DM-CCH rats was associated with increased expression of glial fibrillary acidic protein (GFAP) and β-secretase 1 (BACE1), but decreased expression of choline acetyltransferase (ChAT). Moreover, the levels of all these proteins were significantly alleviated by CM treatment. These results suggest that T2D exacerbated CCH-induced brain damage and cognitive impairment, and CM ameliorated these effects.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP26328041 Cinepazide maleate Cinepazide maleate 26328-04-1 Price
qrcode